story of the week
177Lu-PSMA-617 vs Change of Androgen Receptor Pathway Inhibitor Therapy for Taxane-Naïve Progressive Metastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Lancet 2024 Sep 28;404(10459)1227-1239, MJ Morris, D Castellano, K Herrmann, JS de Bono, ND Shore, KN Chi, M Crosby, JM Piulats, A Fléchon, XX Wei, H Mahammedi, G Roubaud, H Študentová, J Nagarajah, B Mellado, Á Montesa-Pino, E Kpamegan, S Ghebremariam, TN Kreisl, C Wilke, K Lehnhoff, O Sartor, K FizaziFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.